厚生労働科学研究費補助金（難治性疾患克服研究事業） 「Menkes 病・occipital horn 症候群の実態調査、早期診断基準確立、治療法開発に関する研究」 平成23年度 総括・分担研究報告書（page 43/118）[厚生労働科学研究費補助金（難治性疾患克服研究事業） 「Menkes 病・occipital horn 症候群の実態調査、早期診断基準確立、治療法開発に関する研究」 平成23年度 総括・分担研究報告書]

このページは、電子ブック 「厚生労働科学研究費補助金（難治性疾患克服研究事業） 「Menkes 病・occipital horn 症候群の実態調査、早期診断基準確立、治療法開発に関する研究」 平成23年度 総括・分担研究報告書」 内の 43ページ の概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると、今すぐ対象ページへ移動します。

概要：
248 Current Drug Metabolism, 2012, Vol. 13, No. 3 Kodama et al.transporting ATPase gene in occipital horn syndrome and theblotchy mouse. Am. J. Hum. Genet., 1995, 56(3), 570-576.[12] Bull, P.C.; Thoma....

248 Current Drug Metabolism, 2012, Vol. 13, No. 3 Kodama et al.transporting ATPase gene in occipital horn syndrome and theblotchy mouse. Am. J. Hum. Genet., 1995, 56(3), 570-576.[12] Bull, P.C.; Thomas, G.R.; Rommens, J.M.; Forbes, J.R.; Cox, D.W.The Wilson disease gene is a putative copper transporting P-typeATPase similar to the Menkes gene. Nat. Genet., 1993, 5(4), 327-337.[13] Tanzi, R.E.; Petrukhin, K.; Chernov, I.; Pellequer, J.L.; Wasco, W.;Ross, B.; Romano, D.M.; Parano, E.; Pavone, L.; Brzustowicz,L.M.; Devoto, M.; Peppercorn, J.; Bush, A.I.; Sternlieb, I.; Pirastu,M.; Gusella, J.F.; Evgrafov, O.; Penchaszadeh, G.K.; Honig, B.;Edelman, I.S.; Soares, M.B.; Scheinberg, I.H.; Gilliam, T.C. TheWilson disease gene is a copper transporting ATPase with homologyto the Menkes disease gene. Nat. Genet., 1993, 5(4), 344-350.[14] Petrukhin, K.; Fischer, S.G.; Pirastu, M.; Tanzi, R.E.; Chernov, I.;Devoto, M.; Brzustowicz, L.M.; Cayanis, E.; Vitale, E.; Russo, J.J.;Matseoane, D.; Boukhgalter, B.; Wasco, W.; Figus, A.L; Loudianos,J.; Cao, A.; Sternlieb, I.; Evgrafov, O.; Parano, E.; Pavone,L.; Warburton, D.; Ott, J.; Penchaszadeh, G.K.; Scheinberg, I.H.;Gilliam, T.C. Mapping, cloning and genetic characterization of theregion containing the Wilson disease gene. Nat. Genet., 1993, 5(4),338-343.[15] Yamaguchi, Y.; Heiny, M.E.; Gitlin, J.D. Isolation and characterizationof a human liver cDNA as a candidate gene for Wilson disease.Biochem. Biophys. Res. Commun., 1993, 197(1), 271-7.[16] Kodama, H.; Gu, Y.H.; Mizunuma, M. Drug targets in Menkesdisease-prospective developments. Expert. Opin. Ther. Targets.,2001, 5(5), 625-635.[17] Kodama, H. and Fujisawa, C. Copper metabolism and inheritedcopper transporter disorders: molecular mechanisms, screening,and treatment. Metallomics, 2009, 1, 42-52.[18] Kodama, H.; Fujisawa, C.; Bhadhprasit, W. Pathology, clinicalfeatures and treatments of congenital copper metabolic disorders ?Focus on neurologic aspects. Brain Dev., 2011, 243-51.[19] Culotte, V.C.; Gitlin, J.D.; Charles, R.S.; Arthur, L.B.; William,S.S.; David, V. The Metabolism and Molecular Basis of InheritedDisease. New York: McGRAWHILL, 2001, 3105-3126.[20] Van den Berghe, P.V.E.; Klomp, L.W.J. New developments in theregulation of intestinal copper absorption. Nutr. Rev., 2009, 67(11),658-672.[21] Turnlund, J.R. Human whole-body copper metabolism. Am. J. Clin.Nutr., 1998, 67(Suppl), S960-S964.[22] Gupta, A. and Lutsenko, S. Human copper transporters: mechanism,role in human diseases and therapeutic potential. Future Med.Chem., 2009, 1(6), 1125-1142.[23] Miyayama, T.; Suzuki, K.T.; Ogura, Y. Copper accumulation andcompartmentalization in mouse fibroblast lacking metallothioneinand copper chaperone, Atox1. Toxicol. Appl. Pharmacol., 2009,237(2), 205-213.[24] Rodriguez-Granillo, A.; Crespo, A.; Estrin, D.A.; Wittung-Stafshede, P. Copper-transfer mechanism from the human chaperoneAtox1 to a metal-binding domain of Wilson disease protein. J.Phys. Chem. B., 2010, 114(10), 3698-3706.[25] Narindrasorasak, S.; Kulkarni, P.; Deschamps, P.; She, Y.M.;Sarkar, B. Characterization and copper binding properties of humanCOMMD1 (MURR1). Biochem., 2007, 46(11), 3116-3128.[26] Sarkar, B.; Roberts, EA. The puzzle posed by COMMD1, a newlydiscovered protein binding Cu(II). Metallomics, 2011, 3(1), 20-27.[27] van De Sluis, B.; Rothuizen, J.; Pearson, P.L.; van Oost, B.A.;Wijmenga, C. Identification of a new copper metabolism gene bypositional cloning in a purebred dog population. Hum. Mol. Genet.,2002, 11(2), 165-73.[28] Tao, T.Y.; Liu, F.; Klomp, L.; Wijmenga, C.; Gitlin, J.D. The coppertoxicosis gene product Murr1 directly interacts with the Wilsondisease protein. J. Biol. Chem., 2003, 278(43), 41593-41596.[29] Miyayama, T.; Hiraoka, D.; Kawaji, F.; Nakamura, E.; Suzuki, N.;Ogra, Y. Roles of COMM-domain-containing 1 in stability and recruitmentof the copper-transporting ATPase in a mouse hepatomacell line. Biochem. J., 2010, 429(1), 53-61.[30] Kennerson, M.L.; Nicholson, G.A.; Kaler, S.G.; Kowalski, B.;Mercer, J.F.B.; Tang, J.; Llanos, R.M.; Chu, S.; Takata, R.I.;Speck-Martins, C.E.; Beats, J.; Almeida-Souza, L.; Fischer, D.;Timmerman, V.; Taylor, P.E.; Scherer, S.S.; Ferguson, T.A.; Bird,T.D.; Jonghe, P.D.; Feely, S.M.E.; Shy, M.E.; Garbern, J.Y. Missensemutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy. Am. J. Hum. Genet.,2010, 86(3), 343-352.[31] Murata, Y.; Kodama, H.; Abe, T.; Ishida, N.; Nishimura, M.;Levinson, B.; Gitschier, J.; Packman, S. Mutation analysis and expressionof the mottled gene in the macular mouse model ofMenkes disease. Pediatr. Res., 1997, 42(4), 436-442.[32] Qian, Y.; Tiffany-Castiglioni, E.; Welsh, J.; Harris, E.D. Copperefflux from murine microvascular cells requires expression of themenkes disease Cu-ATPase. J. Nutr., 1998, 128(8), 1276-1282.[33] La Fontaine, S. and Mercer, J.F. Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis. Arch.Biochem. Biophys., 2007, 463(2), 149-167.[34] Forbes, J.R. and Cox, D.W. Functional characterization of missensemutations Wilson disease mutation or normal variant? Am. J. Hum.Genet., 1998, 63(6), 1663-1674.[35] Tang, J.; Robertson, S.P.; Lem, K.E.; Godwin, S.C.; Kaler, S.G.Functional copper transport explains neurologic sparing in occipitalhorn syndrome. Genet. Med., 2006, 8(11), 711-718.[36] Tsivkovskii, R.; Eisses, J.F.; Kapian, J.H.; Lutsenko, S. Functionalproperties of the copper transporting ATPase ATP7B (the Wilson’sdisease protein) expressed in insect cells. J. Biol. Chem., 2002,277(2), 976-983.[37] Gu, Y.H.; Kodama, H.; Shiga, K.; Nakata, S.; Yanagawa, Y.;Ozawa, H. A survey of Japanese patients with Menkes disease from1990 to 2003: incidence and early signs before typical symptomaticonset, pointing the way to earlier diagnosis. J. Inherit. Metab. Dis.,2005, 28(4), 473-478.[38] Gu, Y.H.; Kodama, H.; Murata, Y.; Mochizuki, D.; Yanagawa, Y.;Ushijima, H. ATP7A gene mutations in 16 patients with Menkesdisease and a patient with occipital horn syndrome. Am. J. Med.Genet., 2001, 99(3), 217-222.[39] Kodama, H. Gene defects and clinical aspects in Menkes diseaseand occipital horn syndrome. In: Massaro E ed. Handbook of CopperPharmacology. Totowa (U.S.A.); Human Press, 2002, 319-338.[40] Moller, L.B.; Mogensen, M.; Horn, N. Molecular diagnosis ofMenkes disease: Genotype-phenotype correlation. Biochimie, 2009,91(10), 1273-1277.[41] Gu, Y.H.; Kodama, H.; Sato, E.; Mochizuki, D.; Yanagawa, Y.;Takayanagi, M.; Sato, K.; Ogawa, A.; Ushijima, H.; Lee, C.C. Prenataldiagnosis of Menkes disease by genetic analysis and coppermeasurement. Brain Dev., 2002, 24(7), 715-718.[42] Sirleto, P.; Surace, C.; Santos, H.; Bertini, E.; Tomaiuolo, A.C.;Lombardo, A.; Boenzi, S.; Bevivino, E.; Dionisi-Vici, C.; Angioni,A. Lyonization effects of the t(X;16) translocation on the phenotypicexpression in a rare female with Menkes disease. Pediatr.Res., 2009, 65(3), 347-351.[43] Kodama, H.; Murata, Y. Molecular genetics and pathophysiologyof Menkes disease. Pediatr. Int., 1999, 41(4), 430-435.[44] Kodama, H.; Abe, T.; Takama, M.; Takahashi, I.; Kodama, M.;Nishimura, M. Histochemical localization of copper in the intestineand kidney of macular mice: light and electron microscopic study.J. Histochem. Cytochem., 1993, 41(10), 1529-1535.[45] Kodama, H.; Meguro, Y.; Abe, T.; Rayner, M.H.; Suzuki, K.T.;Kobayashi, S.; Nishimura, M. Genetic expression of Menkes diseasein cultured astrocytes of the macular mouse. J. Inherit. Metab.Dis., 1991, 14(6), 896-901.[46] Kodama, H. Recent developments in Menkes disease. J. Inherit.Metab. Dis., 1993, 16(4), 791-799.[47] Murata, Y.; Kodama, H.; Mori, Y.; Kobayashi, M.; Abe, T. Mottledgene expression and copper distribution in the macular mouse, ananimal model for Menkes disease. J. Inherit. Metab. Dis., 1998,21(3), 199-202.[48] Aguilar, M.J.; Chadwick, D.L.; Okuyama, K.; Kamoshita, S. Kinkyhair disease. I. Clinical and pathological features. J. Neuropath. &Exper. Neurol., 1966, 25(4), 507-522.[49] Kodama, H.; Sato, E.; Yanagawa, Y.; Ozawa, H.; Kozuma, T.Biochemical indicator for evaluation of connective tissue abnormalitiesin Menkes' disease. J. Pediatr., 2003, 142(6), 726-728.[50] Kaler, SG.; Goldstein, DS.; Holmes, C.; Salemo, JA.; Gahl, WA.Plasma and cerebrospinal fluid neurochemical pattern in Menkesdisease. Ann. Neurol., 1993, 33(2), 171-175.[51] Agertt, F.; Crippa, A.C.; Lorenzoni, P.J.; Scola, R.H.; Bruck, I.;Paola, L.; Silvado, C.E.; Werneck, L.C. Menkes’s disease: case report.Arq. Neuropsiquiatr., 2007; 65, 157-160.[52] Kodama, H.; Murata, Y.; Kobayashi, M. Clinical manifestationsand treatment of Menkes disease and its variants. Pediatr. Int.,1999, 41(4), 423-429.